Serina Therapeutics, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated March 17, 2026, details a material definitive agreement entered into by Serina Therapeutics, Inc. (the "Company"). The filing reports on a private placement transaction and related corporate governance changes effective as of March 17, 2026, with the initial closing occurring on or before March 20, 2026.
Key Financial Metrics and Transaction Details
- Capital Raised: Investors funded the full $15.0 million of the initial closing tranche as of March 20, 2026.
- Purchase Price: Securities were sold at $2.25 per share of Common Stock (or $2.2499 per Pre-Funded Warrant).
- Future Funding Potential: The agreement allows for additional closings totaling at least $5.0 million and up to $15.0 million within 20 days of the initial closing, with a lead investor backstop obligation.
- Debt Restructuring: As a condition to closing, the Company amended its Senior Unsecured Convertible Promissory Note (dated September 9, 2025), removing further obligations to borrow or loan funds under that note.
- Warrant Terms: Investors received Redeemable Warrants to purchase 50% of the shares purchased at an exercise price of $5.00 per share with a four-year term.
Material Changes and Corporate Governance
- Board Appointment: Gregory H. Bailey, M.D., the lead investor, was appointed Co-Chairman of the Board, serving alongside Executive Chairman Balkrishan "Simba" Gill. This appointment is effective upon the closing of the initial tranche.
- Board Expansion Rights: Investors have the right to designate one additional non-executive director upon the funding of at least $5.0 million by non-lead investors in the first closing or the funding of the first $10.0 million of the second closing.
- Related Party Considerations: Dr. Bailey is a designee of Juvenescence Limited, the Company's largest shareholder. A Special Committee of independent directors evaluated and approved the transaction.
- Stockholder Approval Requirement: The Company will not issue shares to Dr. Bailey until stockholder approval is obtained in accordance with NYSE American rules. The Company will seek this approval at the next annual meeting and, if necessary, call subsequent meetings every 90 days.
Outlook, Risks, and Contingencies
- Warrant Redemption Trigger: The Company may redeem the Redeemable Warrants at $0.01 per share if the Common Stock closing price equals or exceeds $10.00 per share on the business day prior to notice. This right becomes exercisable on the earlier of 30 days after the dosing of the first patient in Cohort 2 of the SER-252 Phase 1b study or September 30, 2026.
- Registration Rights: The Company must file a registration statement for the resale of securities within 45 days of selling at least $20 million of Securities and have it declared effective within 90 days of filing (or sooner if no full review).
- Regulatory Status: The private placement relies on Section 4(a)(2) of the Securities Act and/or Rule 506(b) of Regulation D.
Investor Verification Checklist
- Verify the status of stockholder approval required for Dr. Bailey's share issuance and the timeline for the next annual meeting.
- Confirm the progress of the SER-252 Phase 1b clinical study, specifically the dosing of the first patient in Cohort 2, which triggers warrant redemption rights.
- Monitor the execution of the additional funding tranches (up to $15.0 million) and the appointment of the additional investor-designated director.
- Review the filed Registration Rights Agreement to track the timeline for the resale registration statement filing.
- Assess the impact of the amended Senior Unsecured Convertible Promissory Note on the Company's current debt obligations.